ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Latest Information Update: 16 Jul 2025
At a glance
- Drugs Apalutamide (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS
- Sponsors Aragon Pharmaceuticals; Janssen-Cilag
Most Recent Events
- 24 May 2024 Planned primary completion date changed from 28 Jun 2024 to 30 Jun 2026.
- 02 Jan 2024 Planned End Date changed from 1 Dec 2028 to 29 Dec 2028.
- 02 Jan 2024 Planned primary completion date changed from 1 Jun 2024 to 28 Jun 2024.